WntResearch is active in biotechnology and is developing a therapy to counteract cancer metastases. The company's research is focused on studies of the body's own protein WNT5A, which has been seen in studies to affect the ability of tumor cells to move and spread. The company's drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is being evaluated in the phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer. The company was founded in 2007 and has its headquarters in Malmö.

Quotes for WntResearch AB

Right Now

+/-
0.53
%
5,35%
Latest
10.43
High
10.9
Low
8.111
Volume
3 335
Turnover (SEK)
33 805
Market Value (MSEK)
90,3
Time (Latest trade)

Board

CEO

  • Per Norlén

Chairperson of the Board

  • Christer Nordstedt

Board

  • Åsa Kornfeld
  • Gudrun Anstrén
  • Janna Sand-Dejmek
  • Mats Lindskog
  • Peter Ström
  • Tommy Andersson

Videos

Largest Owners

Name Capital % Votes % Date
Avanza Pension 11,53 11,53 2024-03-26
Nordnet Pensionsförsäkring 6,34 6,34 2024-03-26
Thomas Mellqvist 3,46 3,46 2024-03-26
Niclas Evertsson 2,27 2,27 2024-03-26
Lars-Erik Forsgårdh 2,18 2,18 2024-03-26
Kjell Stenberg 2,15 2,15 2024-03-26
Försäkringsaktiebolaget Skandia 1,92 1,92 2024-03-26
Psykolog JP Gisselgård AS 1,73 1,73 2024-03-26
Stefan Malmkvist 1,61 1,61 2024-03-26
Srch Quality Consulting AB 1,39 1,39 2024-03-26
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream